Carazolol

Carazolol
Clinical data
AHFS/Drugs.com	International Drug Names
ATCvet code	QC07AA90 (WHO) ;
Identifiers
	IUPAC name 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;
CAS Number	57775-29-8;
PubChem CID	71739;
IUPHAR/BPS	569;
ChemSpider	64783;
UNII	29PW75S82A;
ChEMBL	ChEMBL324665;
CompTox Dashboard (EPA)	DTXSID00866648 ;
ECHA InfoCard	100.055.387
Chemical and physical data
Formula	C18H22N2O2
Molar mass	298.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC(CNC(C)C)COc3cccc2c3c1c(cccc1)2;

Carazolol is a high affinity inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.^[1]

References

^ Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. doi:10.1016/0024-3205(79)90102-4. PMID 41147.

External links

Carazolol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Carazolol
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[pmid41147-1] Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. doi:10.1016/0024-3205(79)90102-4. PMID 41147.

[1]